Cat. #156429
IDH1 Mutant Glioma Xenograft (JHH-273) mouse
Cat. #: 156429
Sub-type: Mouse
Availability: 8-10 weeks
Disease: Glial tumor formation
Model: Mutant
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Gregory Riggins
Institute: Johns Hopkins University
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: IDH1 Mutant Glioma Xenograft (JHH-273) mouse
- Research fields: Cancer;Drug development
- Tool sub type: Mouse
- Disease: Glial tumor formation
- Model: Mutant
- Description: An in vivo Isocitrate Dehydrogenase (IDH-1) glioma mouse xenograft model has been developed to further study effective therapies for IDH mutations characterized by increased DNA methylation and production of the common oncometabolite, 2-HG. Difficult grafting cell-culture techniques and current engineered cell line quality have limited additional laboratory studies; however, this model was developed directly from a WHO grade III- glial cell positive cancer patient tissue (JHH273) with a confirmed IDH mutation through DNA sequencing and maintains IDH-1 mutation features observed in human primary glial brain tumors. Additionally, when models were exposed to a demethlyating agent, 5-azacytidine, a reduction in methylation and tumor growth was observed opening the door for more clinical analysis. This model meets a critical need to test drug agents targeting mechanisms involved in glial tumor formation.
- Genetic background: 4â6-week old female athymic nude mice
- Phenotype: 4â6-week old female athymic nude mice
Handling
- Shipping conditions: Embryo/Spermatoza- Dry Ice
Target Details
- Target: IDH1
References
- Borodovsky et al. 2013. Oncotarget. 4(10):1737-47. PMID: 24077805.
